Efficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, Oreochromis niloticus

Streptococcosis is a significant fish disease impacting tilapia culture in Indonesia, causing losses estimated up to IDR 15.0 billion annually. This study aims to assess the efficacy of bivalent and trivalent vaccines containing Streptococcus agalactiae bacteria on tilapia. The formula of the bivale...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Taukhid, Lusiastuti Angela M., Andriyanto Septyan, Sugiani Desy, Sumiati Tuti, Suhermanto Achmad
Formato:	article
Lenguaje:	EN FR
Publicado:	EDP Sciences 2021
Materias:	Environmental sciences GE1-350
Acceso en línea:	https://doaj.org/article/ae3fa63863af48258e09baa530c76233
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ae3fa63863af48258e09baa530c76233
record_format	dspace
spelling	oai:doaj.org-article:ae3fa63863af48258e09baa530c762332021-11-12T11:44:43ZEfficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, Oreochromis niloticus2267-124210.1051/e3sconf/202132202014https://doaj.org/article/ae3fa63863af48258e09baa530c762332021-01-01T00:00:00Zhttps://www.e3s-conferences.org/articles/e3sconf/pdf/2021/98/e3sconf_isffs2021_02014.pdfhttps://doaj.org/toc/2267-1242Streptococcosis is a significant fish disease impacting tilapia culture in Indonesia, causing losses estimated up to IDR 15.0 billion annually. This study aims to assess the efficacy of bivalent and trivalent vaccines containing Streptococcus agalactiae bacteria on tilapia. The formula of the bivalent vaccine contains 75% of S01-196-16 and 25% of N14G isolates (v/v). Trivalent vaccine contains 30%, 35%, and 35% of N14G, NP1050, and SG01-16 isolates (v/v), respectively. A challenge test assessed the efficacy of the vaccines, and it was carried out at 30, 90, and 150 days post-vaccination by artificially infection at LD60. Selected bacteria isolate to be appointed in the challenge test are N14G (biotype 2) and S01-196-16 (biotype 1). Relative Percentage of Survival (RPS) was used as the main indicator of vaccine efficacy. The results revealed that the highest RPS of a bivalent vaccine against S. agalactiae (S01-196-16) was achieved at the first challenge (61.84%), and trivalent vaccine against S. agalactiae (N14G) and S. agalactiae (S01-196-16) was achieved at the first challenge (61.53% and 76.20%, respectively). Bivalent and trivalent S. agalactiae bacteria vaccines are promising “tools” to control streptococcosis on tilapia.TaukhidLusiastuti Angela M.Andriyanto SeptyanSugiani DesySumiati TutiSuhermanto AchmadEDP SciencesarticleEnvironmental sciencesGE1-350ENFRE3S Web of Conferences, Vol 322, p 02014 (2021)
institution	DOAJ
collection	DOAJ
language	EN FR
topic	Environmental sciences GE1-350
spellingShingle	Environmental sciences GE1-350 Taukhid Lusiastuti Angela M. Andriyanto Septyan Sugiani Desy Sumiati Tuti Suhermanto Achmad Efficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, Oreochromis niloticus
description	Streptococcosis is a significant fish disease impacting tilapia culture in Indonesia, causing losses estimated up to IDR 15.0 billion annually. This study aims to assess the efficacy of bivalent and trivalent vaccines containing Streptococcus agalactiae bacteria on tilapia. The formula of the bivalent vaccine contains 75% of S01-196-16 and 25% of N14G isolates (v/v). Trivalent vaccine contains 30%, 35%, and 35% of N14G, NP1050, and SG01-16 isolates (v/v), respectively. A challenge test assessed the efficacy of the vaccines, and it was carried out at 30, 90, and 150 days post-vaccination by artificially infection at LD60. Selected bacteria isolate to be appointed in the challenge test are N14G (biotype 2) and S01-196-16 (biotype 1). Relative Percentage of Survival (RPS) was used as the main indicator of vaccine efficacy. The results revealed that the highest RPS of a bivalent vaccine against S. agalactiae (S01-196-16) was achieved at the first challenge (61.84%), and trivalent vaccine against S. agalactiae (N14G) and S. agalactiae (S01-196-16) was achieved at the first challenge (61.53% and 76.20%, respectively). Bivalent and trivalent S. agalactiae bacteria vaccines are promising “tools” to control streptococcosis on tilapia.
format	article
author	Taukhid Lusiastuti Angela M. Andriyanto Septyan Sugiani Desy Sumiati Tuti Suhermanto Achmad
author_facet	Taukhid Lusiastuti Angela M. Andriyanto Septyan Sugiani Desy Sumiati Tuti Suhermanto Achmad
author_sort	Taukhid
title	Efficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, Oreochromis niloticus
title_short	Efficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, Oreochromis niloticus
title_full	Efficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, Oreochromis niloticus
title_fullStr	Efficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, Oreochromis niloticus
title_full_unstemmed	Efficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, Oreochromis niloticus
title_sort	efficacy of inactive bivalent and trivalent streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, oreochromis niloticus
publisher	EDP Sciences
publishDate	2021
url	https://doaj.org/article/ae3fa63863af48258e09baa530c76233
work_keys_str_mv	AT taukhid efficacyofinactivebivalentandtrivalentstreptococcusagalactiaebacteriabiotype12vaccinesontilapiaoreochromisniloticus AT lusiastutiangelam efficacyofinactivebivalentandtrivalentstreptococcusagalactiaebacteriabiotype12vaccinesontilapiaoreochromisniloticus AT andriyantoseptyan efficacyofinactivebivalentandtrivalentstreptococcusagalactiaebacteriabiotype12vaccinesontilapiaoreochromisniloticus AT sugianidesy efficacyofinactivebivalentandtrivalentstreptococcusagalactiaebacteriabiotype12vaccinesontilapiaoreochromisniloticus AT sumiatituti efficacyofinactivebivalentandtrivalentstreptococcusagalactiaebacteriabiotype12vaccinesontilapiaoreochromisniloticus AT suhermantoachmad efficacyofinactivebivalentandtrivalentstreptococcusagalactiaebacteriabiotype12vaccinesontilapiaoreochromisniloticus
_version_	1718430572348440576

Efficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 & 2) vaccines on tilapia, Oreochromis niloticus

Ejemplares similares